Christopher Nishan Garabedian

Chairman & Chief Executive Officer at Xontogeny LLC

Christopher Nishan Garabedian

Christopher Nishan Garabedian

Chairman & Chief Executive Officer at Xontogeny LLC

Overview
Career Highlights

Xontogeny LLC
Sarepta Therapeutics, Inc.

RelSci Relationships

1576

Number of Boards

9

Birthday

1966

Age

55

Contact Data
Trying to get in touch with Christopher Nishan Garabedian? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Christopher Nishan Garabedian likely has professional access to. A relationship does not necessarily indicate a personal connection.

Senior Vice President, Regulatory Affairs & Clinical Quality Assurance at Rigel Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Investment Officer at Perceptive Advisors LLC

Relationship likelihood: Strong

President & Professor at Keck Graduate Institute of Applied Life Sciences

Relationship likelihood: Strong

Chief Medical Officer at Unity Biotechnology, Inc.

Relationship likelihood: Strong

General Manager, Advanced Monitoring at Baxter Healthcare Corporation

Relationship likelihood: Strong

Member, Advisory Council at Keck Graduate Institute of Applied Life Sciences

Relationship likelihood: Strong

Member, Corporate Relations Board at Keck Graduate Institute of Applied Life Sciences

Relationship likelihood: Strong

Member, Corporate Relations Board at Keck Graduate Institute of Applied Life Sciences

Relationship likelihood: Strong

Member, Corporate Relations Board at Keck Graduate Institute of Applied Life Sciences

Relationship likelihood: Strong

Member, Corporate Relations Board at Keck Graduate Institute of Applied Life Sciences

Relationship likelihood: Strong

Paths to Christopher Nishan Garabedian
Potential Connections via
Relationship Science
You
Christopher Nishan Garabedian
Chairman & Chief Executive Officer at Xontogeny LLC
Education
B.S. in Marketing
Class of 1989
Career History
Chairman & Chief Executive Officer
2016 - Current

Xontogeny LLC operates biotech aggregator company. The firm offers entrepreneurs with guidance and operational support in drug and technology development. The company was founded by Christopher Nishan Garabedian and is headquartered in Boston, MA.

Portfolio Manager, Venture
Current

Founded in 1999, Perceptive Advisors focuses on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. Today, the firm manages approximately $7.3 billion across our strategies.

Vice President, Corporate Strategy
1997 - Prior

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin's lymphoma (NHL), myelofibrosis, small cell lung cancer and prostate cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies

Investments
Details Hidden

Landos Biopharma, Inc. engages in the development and commercialization of novel therapeutics for autoimmune diseases. The firm offers BT-11, a novel, oral, gut-restricted therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway. It also offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.

Events
Speaker
New York City, NY
2013 UBS Global Healthcare Conference

Speaker
Grand Hyatt New York-New York, NY
2012 UBS Global Life Sciences Conference

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Christopher Nishan Garabedian. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Christopher Nishan Garabedian's profile does not indicate a business or promotional relationship of any kind between RelSci and Christopher Nishan Garabedian.